

1654
PATENTS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: **Ellis L. Kline**

Serial No. **09/827,302**

Filed: **APRIL 5, 2001**

For: **METHODS AND COMPOSITIONS
FOR TREATING NEOPLASMS**

Art Unit: **1654**

Examiner: **MELLER, M.**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir :

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

As this Supplemental Information Disclosure Statement is being filed after the issuance of an office action on the merits, pursuant to 37 C.F.R. §1.97(c)(2), the fee of \$180, as set forth in §1.17(p), is authorized herein by Form PTO-2038.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

06/10/2005 MWOLDGE1 00000014 09827302

01 FC:1806

180.00 DP

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on June 6, 2005.

Sima Singaria Kulkarni
Sima Singaria Kulkarni – Reg. No. 43,732

Supplemental Information Disclosure Statement

Serial No. 09/827,302

Page 2 of 2


No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to Deposit Account No. 11-0855.

Respectfully submitted,


Sima Singadia Kulkarni
Reg. No. 43,732

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
404-815-6500
Attorney Docket: 13395-0101 (44448-256971)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
		Application Number		09/827,302	
		Filing Date		April 5, 2001	
		First Named Inventor		Ellis L. Kline	
		Group Art Unit		1651	
		Examiner Name		M. Mellèr	
Sheet	1	of	1	Attorney Docket Number	13395-0101 (44448-256971)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	Simmons, R., <i>et al.</i> , "Regression of Established Methylcholanthrene Tumors by Intratumor Injections of Vibrio Cholerae Neuraminidase," <i>Journal of Surgical Oncology</i> , Vol. 4, No. 4, pp. 298-305 (1972)	
	2	Simmons, R., <i>et al.</i> , "Immunospecific Regression of Methylcholanthrene Fibrosarcoma With The Use of Neuraminidase. II. Intratumor Injections of Neuraminidase," <i>Surgery</i> , Vol. 71, No. 4, pp. 556-564 (1972)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.